These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24819952)

  • 21. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
    BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.
    Slinin Y; Ishani A; Rector T; Fitzgerald P; MacDonald R; Tacklind J; Rutks I; Wilt TJ
    Am J Kidney Dis; 2012 Nov; 60(5):747-69. PubMed ID: 22999165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries.
    Eder S; Leierer J; Kerschbaum J; Rosivall L; Wiecek A; de Zeeuw D; Mark PB; Heinze G; Rossing P; Heerspink HL; Mayer G
    Diab Vasc Dis Res; 2019 Jan; 16(1):47-56. PubMed ID: 30238781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical manifestations and natural history of diabetic kidney disease.
    Ritz E
    Med Clin North Am; 2013 Jan; 97(1):19-29. PubMed ID: 23290727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic kidney disease categories and renal-cardiovascular outcomes in type 2 diabetes without prevalent cardiovascular disease: a prospective cohort study (JDDM25).
    Yokoyama H; Araki S; Haneda M; Matsushima M; Kawai K; Hirao K; Oishi M; Sugimoto K; Sone H; Maegawa H; Kashiwagi A;
    Diabetologia; 2012 Jul; 55(7):1911-8. PubMed ID: 22476921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Novel diagnostic and therapeutic procedures in diabetic nephropathy].
    Pont'uch P
    Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S57-62. PubMed ID: 27124974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care.
    Metsärinne K; Bröijersen A; Kantola I; Niskanen L; Rissanen A; Appelroth T; Pöntynen N; Poussa T; Koivisto V; Virkamäki A;
    Prim Care Diabetes; 2015 Feb; 9(1):31-8. PubMed ID: 25066820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on the management of chronic kidney disease.
    Rivera JA; O'Hare AM; Harper GM
    Am Fam Physician; 2012 Oct; 86(8):749-54. PubMed ID: 23062158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Goal attainment and renal outcomes in patients enrolled in the chronic kidney disease care program in Taiwan: a 3-year observational study.
    Wang Y; Lee YT; Lee WC; Ng HY; Wu CH; Lee CT
    Int J Qual Health Care; 2019 May; 31(4):252-260. PubMed ID: 30060200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective review of diabetic nephropathy patients during referral to the sub-urban nephrology clinic.
    Menon R; Mohd Noor FS; Draman CR; Seman MR; Ghani AS
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):1109-14. PubMed ID: 22982937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations - a registry-based analysis.
    Bramlage P; Lanzinger S; Tittel SR; Hess E; Fahrner S; Heyer CHJ; Friebe M; Buschmann I; Danne T; Seufert J; Holl RW
    BMC Nephrol; 2021 May; 22(1):184. PubMed ID: 34011313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Patient Voice in Health Care Decision Making: The Perspective of People Living with Diabetes and CKD.
    Sadusky T; Hurst C
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):991-992. PubMed ID: 33687966
    [No Abstract]   [Full Text] [Related]  

  • 34. Rate of kidney function decline and factors predicting progression of kidney disease in type 2 diabetes mellitus patients with reduced kidney function: A nationwide retrospective cohort study.
    Kaewput W; Thongprayoon C; Chewcharat A; Rangsin R; Satirapoj B; Kaewput C; Suwannahitatorn P; Bathini T; Mao MA; Cato LD; Harrison AM; Vaitla P; Cheungpasitporn W
    Ther Apher Dial; 2020 Dec; 24(6):677-687. PubMed ID: 31997551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
    Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of renal function on serum concentration of 1,5-anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I-III: A comparative study with HbA1c and glycated albumin.
    Hasslacher C; Kulozik F
    J Diabetes; 2016 Sep; 8(5):712-9. PubMed ID: 26615054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study.
    Moriya T; Tanaka S; Sone H; Ishibashi S; Matsunaga S; Ohashi Y; Akanuma Y; Haneda M; Katayama S
    J Diabetes Complications; 2017 Feb; 31(2):473-478. PubMed ID: 27396240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Higher Quality of Care on Initiation of Long-term Dialysis in Patients With CKD and Diabetes.
    Wu HY; Fukuma S; Shimizu S; Norton EC; Tu YK; Hung KY; Chen MR; Chien KL; Fukuhara S
    Am J Kidney Dis; 2017 Nov; 70(5):666-674. PubMed ID: 28764919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.